What is Dogwood Therapeutics's acquisitions?

Dogwood Therapeutics (DWTX) reported acquisitions of $940.48K in Q4 2024.

What does acquisitions mean?

Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.

Eli LillyLLY

$1.06B—

Avanos MedicalAVNS

$3.4M+41.7%

PTH

Pelthos Therapeutics Inc.PTHS

$690.25K—

Operating income-$5.1M-14.6%

Net income-$5.0M+54.4%

EPS (diluted)-$0.15+98.2%

Cash & equivalents$13.2M-24.6%

Total debt$144.9K-24.2%

Total equity$80.6M+1,038%

Total assets$95.2M-1.8%

Operating cash flow-$4.6M+2.0%

Market cap$54.14M-57.6%

Enterprise value$41.06M-64.7%

Return on equity-64.6%-29.8pp

Debt / equity0×0.0×

Current ratio5.9×-1.6×

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashAcquiredFromAcquisition.

The official record: Dogwood Therapeutics’s 10-K, filed March 18, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Dogwood Therapeutics's acquisitions?: Dogwood Therapeutics (DWTX) reported acquisitions of $940.48K in Q4 2024.
What does acquisitions mean?: Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.